Click the Why column to see why an item matched the search.
| Match | Type | Why |
|---|
| Association between familial atrial fibrillation and risk of new-onset atrial fibrillation. | Academic Article |
Why?
|
| Atrial fibrillation and heart failure parallels: lessons for atrial fibrillation prevention. | Academic Article |
Why?
|
| Early-life antecedents of atrial fibrillation: place of birth and atrial fibrillation-related mortality. | Academic Article |
Why?
|
| Parental atrial fibrillation as a risk factor for atrial fibrillation in offspring. | Academic Article |
Why?
|
| Family history of atrial fibrillation is associated with earlier-onset and more symptomatic atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. | Academic Article |
Why?
|
| Anemia is associated with bleeding and mortality, but not stroke, in patients with atrial fibrillation: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. | Academic Article |
Why?
|
| Apixaban versus warfarin in patients with atrial fibrillation according to prior warfarin use: results from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial. | Academic Article |
Why?
|
| Association Between Atrial Fibrillation Symptoms, Quality of Life, and Patient Outcomes: Results From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). | Academic Article |
Why?
|
| Association Between Warfarin Control Metrics and Atrial Fibrillation Outcomes in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation. | Academic Article |
Why?
|
| Blood Pressure Control and Risk of Stroke or Systemic Embolism in Patients With Atrial Fibrillation: Results From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial. | Academic Article |
Why?
|
| Design and rationale of Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation: a global registry program on long-term oral antithrombotic treatment in patients with atrial fibrillation. | Academic Article |
Why?
|
| Drivers of hospitalization for patients with atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). | Academic Article |
Why?
|
| Early adoption of dabigatran and its dosing in US patients with atrial fibrillation: results from the outcomes registry for better informed treatment of atrial fibrillation. | Academic Article |
Why?
|
| Early therapeutic persistence on dabigatran versus warfarin therapy in patients with atrial fibrillation: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. | Academic Article |
Why?
|
| Factor V Leiden and risk of ischemic stroke in nonvalvular atrial fibrillation: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. | Academic Article |
Why?
|